Protocol Ledger

NCT07193901 · Phase II · COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

Interventional Phase II clinical trial protocol NCT07193901 sponsored by Sichuan Purity Pharmaceutical Technology Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-27 Enrollment: 98 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07193901
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07193901
Protocol FieldVerified Registry Value
NCT IdentifierNCT07193901
Consolidated Lead SponsorSichuan Purity Pharmaceutical Technology Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment98 participants (ACTUAL)
Registered Start Date2025-05-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07193901
Hospital Research SiteLocationSite Profile
The Second Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Nanchang UniversityNanchang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI